Abrine Elicits Liver Carcinoma Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade by Modulating PD-L1 Signaling

Figure 6

KAT5 knockdown suppresses T cell function. (a–c) The unstimulated or activated PBMCs were set on top chambers of the Transwell; the liver cancer cells depleted of KAT5 were placed in the bottom chambers. The level of PD-L1 in HepG2 cells (a) were checked by flow cytometry. The percentages of CD4+/PD-1+ T cells (b) and CD8+/PD-1+ T cells (c) were checked by flow cytometry. (d) The PD-L1 level of HepG2 cells under treatment with conditioned medium of PBMCs detected by flow cytometry.

(a)

(b)

(c)

(d)